Thyroid Cancer MDx Firm Veractye Raises $28M in Series C Round | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Veracyte today announced the final tranche of its Series C financing round raising $28 million.

Proceeds will go toward commercial expansion of its gene expression-based diagnostic tool called Afirma Thyroid FNA Analysis for thyroid cancer and the development of its product pipeline.

GE Ventures was a new investor in the round. Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, Versant Ventures, and all previous investors participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.